944 Stock Overview
Manufactures and distributes microbiological media, reagents, and equipment for in vitro diagnostics in Poland. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
My Notes
Capture your thoughts, links and company narrative
BioMaxima S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł2.19 |
| 52 Week High | zł3.93 |
| 52 Week Low | zł2.19 |
| Beta | -2.41 |
| 1 Month Change | -18.89% |
| 3 Month Change | -26.26% |
| 1 Year Change | -37.25% |
| 3 Year Change | -58.87% |
| 5 Year Change | n/a |
| Change since IPO | -65.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| 944 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -8.8% | -2.9% | -2.6% |
| 1Y | -37.2% | -8.5% | 6.9% |
Return vs Industry: 944 underperformed the German Medical Equipment industry which returned -8.5% over the past year.
Return vs Market: 944 underperformed the German Market which returned 6.9% over the past year.
Price Volatility
| 944 volatility | |
|---|---|
| 944 Average Weekly Movement | 5.0% |
| Medical Equipment Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 944 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 944's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 115 | Lukasz Urban | www.biomaxima.com |
BioMaxima S.A. manufactures and distributes microbiological media, reagents, and equipment for in vitro diagnostics in Poland. Its primary products include analyzers and diagnostic reagents for testing the biochemical parameters of blood and other body fluids; systems for the determination of drug resistance of microorganisms; quick diagnostic tests for detecting infectious diseases, cancer markers, heart attack markers, and addictive substances and readers; urine analysis systems; hematology analyzers and reagents; ionselective analyzers and reagents; reagents and immunological analyzers of cardiac markers; glucometers for professional use; and analyzers for gasometric tests and critical blood parameters tests. The company also provides surfaces and air controls; antibiotics discs and MIC strips; and chromogenic, dehydrated, and prepared culture media; additives and supplements for media; microbank microorganism storage systems; and veterinary products.
BioMaxima S.A. Fundamentals Summary
| 944 fundamental statistics | |
|---|---|
| Market cap | €11.12m |
| Earnings (TTM) | -€106.51k |
| Revenue (TTM) | €11.49m |
1.0x
P/S Ratio-104.4x
P/E RatioIs 944 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 944 income statement (TTM) | |
|---|---|
| Revenue | zł48.97m |
| Cost of Revenue | zł26.76m |
| Gross Profit | zł22.21m |
| Other Expenses | zł22.67m |
| Earnings | -zł454.00k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 45.35% |
| Net Profit Margin | -0.93% |
| Debt/Equity Ratio | 24.7% |
How did 944 perform over the long term?
See historical performance and comparisonDividends
3.5%
Current Dividend Yield-363%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 16:34 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BioMaxima S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|